2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Antibody-drug conjugates (ADCs) represent a breakthrough in tumor-targeted therapy, showing promise in both solid tumors and hematological malignancies. By 1 September 2025, more than 370 ADC candidates had entered clinical development, 17 unique products had received at least one regulatory approval worldwide, and mor...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
